Boundless Bio, Inc. (BOLD)

NASDAQ: BOLD · IEX Real-Time Price · USD
11.29
-0.34 (-2.92%)
At close: Apr 12, 2024, 4:00 PM
11.01
-0.28 (-2.48%)
After-hours: Apr 12, 2024, 6:16 PM EDT
-2.92%
Market Cap 251.08M
Revenue (ttm) n/a
Net Income (ttm) -49.43M
Shares Out 22.24M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,958
Open 11.50
Previous Close 11.63
Day's Range 11.20 - 11.90
52-Week Range 11.20 - 15.24
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 3, 2024

About BOLD

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Using our proprietary Spyglass platform, we identify targets essential for ecDNA functionality in oncogene amplified cancer cells, then design and develop small molecule drugs called ecDNA-directed therapeutic candidates (ecD... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 28, 2024
Employees 72
Stock Exchange NASDAQ
Ticker Symbol BOLD
Full Company Profile

Financial Performance

Financial Statements

News

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev...

2 days ago - Business Wire

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev...

5 days ago - Business Wire

Boundless Bio Announces Pricing of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients wit...

17 days ago - Business Wire

Oncology biotech Boundless Bio files for a $100 million IPO

Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.

5 weeks ago - Renaissance Capital

Boundless Bio Eyes Nasdaq: Unveiling Cancer Therapy Innovation and IPO Ambitions

Boundless Bio, set to list on Nasdaq as BOLD, unveils its innovative cancer treatment strategy. A significant move reflecting investor confidence.

5 weeks ago - BNN

Boundless Bio IPO Registration Document (S-1)

Boundless Bio has filed to go public with an IPO on the NASDAQ.

5 weeks ago - SEC